PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.07%
Revenue growth of 1.07% while AVGO is flat. Bruce Berkowitz would check if a small edge can widen further.
-6.06%
Negative gross profit growth while AVGO is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-10.44%
Negative EBIT growth while AVGO is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-10.44%
Negative operating income growth while AVGO is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-4.25%
Negative net income growth while AVGO stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.44%
Negative EPS growth while AVGO is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.27%
Negative diluted EPS growth while AVGO is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.21%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.72%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.46%
Dividend growth of 0.46% while AVGO is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
102.70%
OCF growth of 102.70% while AVGO is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
243.37%
FCF growth of 243.37% while AVGO is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
91.91%
10Y CAGR of 91.91% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
76.29%
5Y CAGR of 76.29% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
17.50%
3Y CAGR of 17.50% while AVGO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
123.71%
OCF/share CAGR of 123.71% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
171.96%
OCF/share CAGR of 171.96% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-13.46%
Negative 3Y OCF/share CAGR while AVGO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
311.00%
10Y net income/share CAGR of 311.00% while AVGO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
66.06%
Net income/share CAGR of 66.06% while AVGO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
11.12%
3Y net income/share CAGR of 11.12% while AVGO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
100.48%
Equity/share CAGR of 100.48% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
16.45%
Equity/share CAGR of 16.45% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
5.88%
Equity/share CAGR of 5.88% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
361.29%
Dividend/share CAGR of 361.29% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
366.79%
Dividend/share CAGR of 366.79% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
652488.96%
3Y dividend/share CAGR of 652488.96% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-2.04%
Firm’s AR is declining while AVGO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-4.60%
Inventory is declining while AVGO stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.68%
Asset growth of 0.68% while AVGO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
2.34%
BV/share growth of 2.34% while AVGO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
3.89%
R&D growth of 3.89% while AVGO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-8.88%
We cut SG&A while AVGO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.